

Vorhersagegrenzen von klinischen Modellen bei fortgeschrittenen nicht seminomatösen Hodentumoren

Tim Nestler, Pia Paffenholz, Simon Hoier, David Pfister, Martin Hellmich, Axel Heidenreich

Literatur

1. Albers P, Albrecht W, Algaba F, Bokemeyer C, Cohn-Cedermark G, Fizazi K, et al Guidelines on Testicular Cancer: 2015 Update. *Eur Urol.* 2015;68(6):1054-68
2. Heidenreich A, Haidl F, Paffenholz P, Pape C, Neumann U, Pfister D. Surgical management of complex residual masses following systemic chemotherapy for metastatic testicular germ cell tumours. *Ann Oncol.* 2017;28(2):362-7
3. Winter C, Pfister D, Busch J, Bingol C, Ranft U, Schrader M, et al Residual tumor size and IGCCCG risk classification predict additional vascular procedures in patients with germ cell tumors and residual tumor resection: a multicenter analysis of the German Testicular Cancer Study Group. *Eur Urol.* 2012;61(2):403-9
4. Nini A, Konieczny M, Winter C, Lusch A, Krauspe R, Albers P. Surgical management and outcomes of patients with bone metastases in germ cell tumors: A case series. *Urol Oncol.* 2018;36(2):82e1-e5
5. Carver BS, Shayegan B, Serio A, Motzer RJ, Bosl GJ, Sheinfeld J. Long-term clinical outcome after postchemotherapy retroperitoneal lymph node dissection in men with residual teratoma. *J Clin Oncol.* 2007;25(9):1033-7
6. Steyerberg EW, Keizer HJ, Fossa SD, Sleijfer DT, Toner GC, Schraffordt Koops H, et al Prediction of residual retroperitoneal mass histology after chemotherapy for metastatic nonseminomatous germ cell tumor: multivariate analysis of individual patient data from six study groups. *J Clin Oncol.* 1995;13(5):1177-87
7. Mao Y, Hedgire S, Prapruttam D, Harisinghani M. Predictive models for lymph node metastases in patients with testicular germ cell tumors. *Abdom Imaging.* 2015;40(8):3196-205
8. Onozawa M, Kawai K, Yamamoto T, Hinotsu S, Tsukamoto S, Hattori K, et al Clinical parameters that predict histology of postchemotherapy retroperitoneal lymph node mass in testicular cancer. *Int J Urol.* 2004;11(7):535-41
9. Li XD, Guo SJ, Chen SL, Liu ZF, Dong P, Zhang ZL, et al [Clinical outcome of postchemotherapy retroperitoneal lymph node dissection and predicting retroperitoneal histology in advanced nonseminomatous germ cell tumours of the testis]. *Zhonghua Wai Ke Za Zhi.* 2017;55(8):603-7

10. Spiess PE, Brown GA, Pisters LL, Liu P, Tu SM, Evans JG, et al Viable malignant germ cell tumor in the postchemotherapy retroperitoneal lymph node dissection specimen: can it be predicted using clinical parameters? *Cancer*. 2006;107(7):1503-10
11. Vergouwe Y, Steyerberg EW, Foster RS, Sleijfer DT, Fossa SD, Gerl A, et al Predicting retroperitoneal histology in postchemotherapy testicular germ cell cancer: a model update and multicentre validation with more than 1000 patients. *Eur Urol*. 2007;51(2):424-32
12. Leao R, Nayan M, Punjani N, Jewett MAS, Fadaak K, Garisto J, et al A New Model to Predict Benign Histology in Residual Retroperitoneal Masses After Chemotherapy in Nonseminoma. *Eur Urol Focus*. 2018
13. Steyerberg EW, Gerl A, Fossa SD, Sleijfer DT, de Wit R, Kirkels WJ, et al Validity of predictions of residual retroperitoneal mass histology in nonseminomatous testicular cancer. *J Clin Oncol*. 1998;16(1):269-74
14. Albers P, Siener R, Krege S, Schmelz HU, Dieckmann KP, Heidenreich A, et al Randomized phase III trial comparing retroperitoneal lymph node dissection with one course of bleomycin and etoposide plus cisplatin chemotherapy in the adjuvant treatment of clinical stage I Nonseminomatous testicular germ cell tumors: AUO trial AH 01/94 by the German Testicular Cancer Study Group. *J Clin Oncol*. 2008;26(18):2966-72
15. Dieckmann KP, Radtke A, Geczi L, Matthies C, Anheuser P, Eckardt U, et al Serum Levels of MicroRNA-371a-3p (M371 Test) as a New Biomarker of Testicular Germ Cell Tumors: Results of a Prospective Multicentric Study. *J Clin Oncol*. 2019;37(16):1412-23
16. Dieckmann KP, Radtke A, Spiekermann M, Balks T, Matthies C, Becker P, et al Serum Levels of MicroRNA miR-371a-3p: A Sensitive and Specific New Biomarker for Germ Cell Tumours. *Eur Urol*. 2017;71(2):213-20.
17. Leao R, van Agthoven T, Figueiredo A, Jewett MAS, Fadaak K, Sweet J, et al Serum miRNA Predicts Viable Disease after Chemotherapy in Patients with Testicular Nonseminoma Germ Cell Tumor. *J Urol*. 2018;200(1):126-35
18. Baessler B, Nestler T, Pinto Dos Santos D, Paffenholz P, Zeuch V, Pfister D, et al Radiomics allows for detection of benign and malignant histopathology in patients with metastatic testicular germ cell tumors prior to post-chemotherapy retroperitoneal lymph node dissection. *Eur Radiol*. 2019